Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 8.7% – What’s Next?

Esperion Therapeutics, Inc. (NASDAQ:ESPR)’s stock price rose 8.7% during mid-day trading on Friday . The company traded as high as $2.76 and last traded at $2.76. Approximately 2,417,710 shares were traded during mid-day trading, a decline of 60% from the average daily volume of 6,116,351 shares. The stock had previously closed at $2.54.

Analyst Ratings Changes

ESPR has been the subject of a number of recent research reports. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Needham & Company LLC decreased their target price on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Wednesday.

Esperion Therapeutics Stock Up 10.2 %

The company has a market capitalization of $551.71 million, a PE ratio of -4.31 and a beta of 0.96. The company has a 50-day moving average price of $2.09 and a two-hundred day moving average price of $2.16.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Eaton Financial Holdings Company LLC purchased a new position in Esperion Therapeutics during the third quarter worth about $73,000. Barclays PLC lifted its stake in shares of Esperion Therapeutics by 99.6% in the 3rd quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock valued at $510,000 after acquiring an additional 154,509 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Esperion Therapeutics by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after acquiring an additional 171,609 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in Esperion Therapeutics during the 3rd quarter valued at about $606,000. Finally, Anson Funds Management LP purchased a new position in Esperion Therapeutics during the 3rd quarter valued at about $540,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.